4-HO-MET

Use and effects

In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the dose range of 4-HO-MET as 10 to 20mg orally and its duration as 4 to 6hours. However, a wider recreational dose range of 2 to 45mg or more orally, with a typical dose estimate of 15mg, has also been reported. The drug's onset is said to be within 30minutes.

The effects of 4-HO-MET have been reported to include pupil dilation, euphoria, tingling sensations, perceptual changes, closed- and open-eye visuals, synesthesia, time dilation, intensified perceptions, thoughts, and feelings, and a general change in thought processes. Other specific effects include alteration of color and form, feeling sounds, and a wave-like experience with alternation between near-normal perception one moment and a "swirl of altered concept" the next moment.

4-HO-MET is said to produce qualitative effects very similar to those of psilocin. Shulgin has stated that he doubts it could be distinguished from psilocin in any blinded clinical study. However, the drug has also been described as being relatively or very light, more clear-headed and functional, and having less head space. On the other hand, it is said to still produce strong psychedelic visuals. This profile of effects has been described as being analogous to the case of 2C-B.

In addition to its use on its own, 4-HO-MET, along with the related tryptamine psychedelic 5-MeO-MiPT, is employed at low doses as a component of the MDMA-mimicking Borax combo.

Contraindications

Interactions

Pharmacology

Pharmacodynamics

4-HO-MET binds to various serotonin receptors and is known to act as an agonist of the serotonin 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1A receptors. It is thought that the hallucinogenic effects of serotonergic psychedelics like 4-HO-MET are mediated by serotonin 5-HT2A receptor activation.

Pharmacokinetics

The metabolism of 4-HO-MET has been studied.

Chemistry

4-HO-MET, also known as 4-hydroxy-N-methyl-N-ethyltryptamine, is a substituted tryptamine and 4-hydroxytryptamine. It is the 4-hydroxy derivative of N-methyl-N-ethyltryptamine (MET) and is a close analogue of psilocin (4-hydroxy-N,N-dimethyltryptamine; 4-HO-DMT).

Synthesis

The chemical synthesis of 4-HO-MET has been described.

Analogues

Analogues of 4-HO-MET include psilocin (4-HO-DMT), 4-HO-DET (ethocin), 4-HO-MiPT (miprocin), 4-HO-DPT (deprocin), 4-HO-MPT (meprocin), 4-HO-DALT (dalocin), and 4-HO-MALT (malocin), among others. 4-AcO-MET (metacetin) and 4-PrO-MET are ester prodrugs of 4-HO-MET. Other analogues of 4-HO-MET include methylethyltryptamine (MET), 5-HO-MET, and 5-MeO-MET.

History

4-HO-MET was first synthesized and discovered by Alexander Shulgin in the 1970s. It was first described in the scientific literature by David Repke and colleagues by 1981. Subsequently, 4-HO-MET was described by Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved) in 1997 as being- aside from its synthesis- indistinguishable from any other ethyl homologue. It was encountered as a novel recreational and designer drug in Europe by 2008.

Society and culture

Legal status

Canada

4-HO-MET is not a controlled substance in Canada as of 2025.

Finland

Scheduled in the "government decree on psychoactive substances banned from the consumer market".

Germany

4-HO-MET is ruled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG) since July 18, 2019. Production and Import with intent to distribute is punishable. Possession is forbidden but not punishable, although ordering it in small quantities can still be seen as an intent to distribute it and be punished.

4-Propionoxy-N-methyl-N-ethyltryptamine (also referred to as 4-PrO-MET) is the ester prodrug of 4-HO-MET. Unlike many other tryptamine derivatives, it is currently not explicitly listed under the German Neue-psychoaktive-Stoffe-Gesetz (NpSG). This means that, while its use as a recreational substance is not legally permitted, the compound may be obtained and handled for legitimate research purposes, provided all other relevant legal requirements and safety regulations are observed.

Sweden

The Swedish Riksdag added 4-HO-MET to Schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6.

United Kingdom

4-HO-MET is a class A drug in the United Kingdom, as a result of the tryptamine catch-all clause.

United States

4-HO-MET is not scheduled at the federal level in the United States, but it is possible that it could be considered an analogue of psilocin, in which case purchase, sale, or possession could be prosecuted under the Federal Analogue Act.

It is a schedule I substance in some states, such as South Dakota and West Virginia.

References

References

1. "§ 54.1-3446. Schedule I.".
2. (2008). "2015 Annual Reports on the implementation of Council Decision 2005/387/JHA".
3. {{CiteTiHKAL https://www.erowid.org/library/books_online/tihkal/tihkal21.shtml
4. (2003). "Hallucinogens: A Forensic Drug Handbook". Elsevier Science.
5. (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol.
6. (2011). "Heaven and hell--a phenomenological study of recreational use of 4-HO-MET in Sweden". J Psychoactive Drugs.
7. (January 2020). "A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines". Human Psychopharmacology.
8. (23 June 2023). "Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine". [[Multidisciplinary Association for Psychedelic Studies]].
9. (28 November 2023). "POD 92: Understanding and Improving MDMA with Dr. Matthew Baggott". Patreon.
10. (14 December 2022). "Borax Combo (Synonyms: Blue Bliss)". National Association of Drug Diversion Investigators (NADDI).
11. (August 2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens". European Neuropsychopharmacology.
12. (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacol Transl Sci.
13. (April 2023). "Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter". J Pharmacol Exp Ther.
14. (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacol Transl Sci.
15. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther.
16. (April 2016). "Psychedelics". Pharmacol Rev.
17. (September 2018). "Study of the in vitro and in vivo metabolism of 4-HO-MET". Forensic Sci Int.
18. "4-Pro-MET".
19. (2018). "The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines". Front Integr Neurosci.
20. (1981). "Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-( N -methyl- N -alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols". Journal of Heterocyclic Chemistry.
21. "Controlled Drugs and Substances Act".
22. "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista". Finish Ministry of Justice.
23. (2012-04-20). "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika". Elanders Sverige AB.
24. "21 U.S. Code § 841 - Prohibited acts A".
25. "Chapter 34-20B Drugs and Substances Control".
26. "Chapter 60A. Uniform Controlled Substances Act".